We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

165 hedge funds and large institutions have $324M invested in Tvardi Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 70 increasing their positions, 44 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $1.01M

59% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 44

2% more capital invested

Capital invested by funds: $318M → $324M (+$6.07M)

0.02% less ownership

Funds ownership: 1.8% → 1.79% (-0.02%)

8% less funds holding

Funds holding: 179 → 165 (-14)

46% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 26

Holders
165
Holders Change
-14
Holders Change %
-7.82%
% of All Funds
2.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
70
Reduced
44
Closed
26
Calls
$1.89M
Puts
$1.01M
Net Calls
+$879K
Net Calls Change
-$2.01M

Top Buyers

Rank Fund Capital Flow
1
ClearBridge Investments
ClearBridge Investments
New York
+$4.4M
2
BlackRock
BlackRock
New York
+$2.31M
3
LCG
Lisanti Capital Growth
New York
+$1.6M
4
KCM
Kingdon Capital Management
New York
+$1.51M
5
Morgan Stanley
Morgan Stanley
New York
+$1.42M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$7.11M
2
CSS
Cubist Systematic Strategies
Connecticut
-$2.54M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.62M
4
ACM
Altium Capital Management
New York
-$1.61M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
MPWT
151
MassMutual Private Wealth & Trust
Connecticut
$2K +$1.09K +3 +150%
US Bancorp
152
US Bancorp
Minnesota
$2K +$2.17K +6 +600%
PTC
153
Private Trust Company
Ohio
$2K +$2.54K +7 New
BHWM
154
Beaird Harris Wealth Management
Texas
$1K – – –
CFGS
155
Concourse Financial Group Securities
Alabama
$1K – – –
SIS
156
Sound Income Strategies
Florida
$1K – – –
TWA
157
TCI Wealth Advisors
Arizona
$1K – – –
VCM
158
Versant Capital Management
Arizona
$1K – – –
RWML
159
RAFFA WEALTH MANAGEMENT, LLC
District of Columbia
$721 – – –
Millennium Management
160
Millennium Management
New York
– -$7.11M -21,616 Closed
CSS
161
Cubist Systematic Strategies
Connecticut
– -$2.54M -7,719 Closed
Two Sigma Investments
162
Two Sigma Investments
New York
– -$1.24M -3,779 Closed
GCP
163
GSA Capital Partners
United Kingdom
– -$1.1M -3,348 Closed
CM
164
Caption Management
Oklahoma
– -$383K -1,164 Closed
AI
165
Atom Investors
Texas
– -$244K -741 Closed
Squarepoint
166
Squarepoint
New York
– -$239K -728 Closed
EGM
167
Engineers Gate Manager
New York
– -$160K -486 Closed
AQR Capital Management
168
AQR Capital Management
Connecticut
– -$160K -485 Closed
OC
169
Oppenheimer & Co
New York
– -$156K -476 Closed
Two Sigma Advisers
170
Two Sigma Advisers
New York
– -$155K -472 Closed
FCBT
171
First Citizens Bank & Trust
North Carolina
– -$143K -437 Closed
QT
172
Quantamental Technologies
New York
– -$98K -300 Closed
Rafferty Asset Management
173
Rafferty Asset Management
New York
– -$97K -295 Closed
Handelsbanken Fonder
174
Handelsbanken Fonder
Sweden
– -$97K -294 Closed
Federated Hermes
175
Federated Hermes
Pennsylvania
– -$29K -89 Closed
4 5 6
7
8

TVRD Hedge Fund Activity: Q3 2022 in Review

165 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2022, worth a combined $324M — up 1.9% from $318M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of TVRD and 14 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 70 added.

The largest buyer was ClearBridge Investments, opening a new position worth an estimated $4.4M. The largest seller was Millennium Management, exiting entirely with an estimated $7.11M sold.

  • 165 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2022, down from 179 in Q2 2022.
  • Funds reported $324M of Tvardi Therapeutics stock for Q3 2022, up 1.9% quarter-over-quarter.
  • 14 funds opened new Tvardi Therapeutics positions in Q3 2022 and 26 closed out, a net change of -12 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2022 was ClearBridge Investments, an estimated $4.4M added.
  • The largest Tvardi Therapeutics seller in Q3 2022 was Millennium Management, an estimated $7.11M sold.

Based on aggregated 13F filings for Q3 2022.